Global Dexamethasone Drug Market
Global Dexamethasone Drug Market

Dexamethasone Drug Comprehensive Study by Application (Anti-inflammatory and immunosuppressant effects, Respiratory Distress Syndrome, COVID-19, Others), Patient type (Adult, Pediatric, Geriatric), Distribution Channel (Online, Offline), Formulation (Liquid, Tablet, Solution for injection, Others), Drug class (Corticosteroid, Glucocorticoid)

Dexamethasone Drug Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Sep 2020 Edition 203 Pages 214 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Dexamethasone Drug Market Overview:
Dexamethason Drug is used in a wide range of conditions to treat its anti-inflammatory and immunosuppressant effects. In addition, This drug is inexpensive is used to treat conditions such as arthritis, blood/hormone/immune system disorders, allergic reactions, certain skin, and eye conditions, breathing problems, certain bowel disorders, and certain cancers. It is also used as a test for an adrenal gland disorder According to the research Dexamethasone, a despicable, widely-available steroid, is the latest drug push by experts in the UK as a possible treatment for COVID-19, with evidence suggesting that it can successfully reduce deaths from the virus by up to one third in the severely-ill patient,it costs around £5 per dose, but it costs as little as .50 in India. Increasing the Number of cases of COVID 19 is one of the key driving factor of growth of this Dexamathason Drugs in the market

Market Drivers
  • The climb of dexamethasone as a lifesaving treatment for critically ill COVID-19 patients due to a sudden outburst is key driving factor of growth
  • The increasing prevalence of diseases will act as major driving factors in the growth of the global Dexamethasone market


Restraints
  • Adevers effect of Dexamethason Drug

Opportunities
  • The increasing Interest of Government due to the sudden outbursts of COVID 19 worldwide and high investment in R &D in the Deamethasone market will create the opportunity for the market players.

Challenges
  • Key Competition between Key Players


Competitive Landscape:
The majority of the dexamethasone Drug is being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies
Some of the key players profiled in the report are Sanofi (France), GlaxoSmithKline Plc (United Kingdom), Wockhardt Ltd. (India), Eli Lilly and Company (United States), Johnson & Johnson (J&J) (United States), Cadila Healthcare Ltd. (India), Cipla (India), Hikma Pharmaceuticals (United Kingdom), Aché (Brazil) and AbbVie Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like F Hoffmann-La Roche Ltd (Switzerland), Novartis (Switzerland) and Pfizer Inc (United States). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Dexamethasone Drug market by 2025. Considering Market by Patient type, the sub-segment i.e. Adult will boost the Dexamethasone Drug market. Considering Market by Distribution Channel, the sub-segment i.e. Online will boost the Dexamethasone Drug market. Considering Market by Formulation, the sub-segment i.e. Liquid will boost the Dexamethasone Drug market. Considering Market by Drug class, the sub-segment i.e. Corticosteroid will boost the Dexamethasone Drug market.

Market Highlights:


On June 2020 Dexamethasone Drug has proved as the first life-saving drug for COVID 19 this drug had been used to treat patients in the United Kingdom from the start of the pandemic, up to 5,000 lives possibly have been saved. and In June 2019 Johnson and Johnson united states based company has announced the approval for their product name DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone for treating newly diagnosed patients with multiple myeloma who are eligible for ASCT.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Dexamethasone Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Dexamethasone Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Dexamethasone Drug Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Application
  • Anti-inflammatory and immunosuppressant effects
  • Respiratory Distress Syndrome
  • COVID-19
  • Others
By Patient type
  • Adult
  • Pediatric
  • Geriatric

By Distribution Channel
  • Online
  • Offline

By Formulation
  • Liquid
  • Tablet
  • Solution for injection
  • Others

By Drug class
  • Corticosteroid
  • Glucocorticoid

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. The climb of dexamethasone as a lifesaving treatment for critically ill COVID-19 patients due to a sudden outburst is key driving factor of growth
        • 3.2.2. The increasing prevalence of diseases will act as major driving factors in the growth of the global Dexamethasone market
      • 3.3. Market Challenges
        • 3.3.1. Key Competition between Key Players
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Dexamethasone Drug, by Application, Patient type, Distribution Channel, Formulation and Drug class (value, volume and price ) (2014-2019)
      • 5.1. Introduction
      • 5.2. Global Dexamethasone Drug (Value)
        • 5.2.1. Global Dexamethasone Drug by: Application (Value)
          • 5.2.1.1. Anti-inflammatory and immunosuppressant effects
          • 5.2.1.2. Respiratory Distress Syndrome
          • 5.2.1.3. COVID-19
          • 5.2.1.4. Others
        • 5.2.2. Global Dexamethasone Drug by: Patient type (Value)
          • 5.2.2.1. Adult
          • 5.2.2.2. Pediatric
          • 5.2.2.3. Geriatric
        • 5.2.3. Global Dexamethasone Drug by: Distribution Channel (Value)
          • 5.2.3.1. Online
          • 5.2.3.2. Offline
        • 5.2.4. Global Dexamethasone Drug by: Formulation (Value)
          • 5.2.4.1. Liquid
          • 5.2.4.2. Tablet
          • 5.2.4.3. Solution for injection
          • 5.2.4.4. Others
        • 5.2.5. Global Dexamethasone Drug by: Drug class (Value)
          • 5.2.5.1. Corticosteroid
          • 5.2.5.2. Glucocorticoid
      • 5.3. Global Dexamethasone Drug (Volume)
        • 5.3.1. Global Dexamethasone Drug by: Application (Volume)
          • 5.3.1.1. Anti-inflammatory and immunosuppressant effects
          • 5.3.1.2. Respiratory Distress Syndrome
          • 5.3.1.3. COVID-19
          • 5.3.1.4. Others
        • 5.3.2. Global Dexamethasone Drug by: Patient type (Volume)
          • 5.3.2.1. Adult
          • 5.3.2.2. Pediatric
          • 5.3.2.3. Geriatric
        • 5.3.3. Global Dexamethasone Drug by: Distribution Channel (Volume)
          • 5.3.3.1. Online
          • 5.3.3.2. Offline
        • 5.3.4. Global Dexamethasone Drug by: Formulation (Volume)
          • 5.3.4.1. Liquid
          • 5.3.4.2. Tablet
          • 5.3.4.3. Solution for injection
          • 5.3.4.4. Others
        • 5.3.5. Global Dexamethasone Drug by: Drug class (Volume)
          • 5.3.5.1. Corticosteroid
          • 5.3.5.2. Glucocorticoid
      • 5.4. Global Dexamethasone Drug (Price)
    • 6. Dexamethasone Drug: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2019)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. Sanofi (France)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. GlaxoSmithKline Plc (United Kingdom)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. Wockhardt Ltd. (India)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Eli Lilly and Company (United States)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Johnson & Johnson (J&J) (United States)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Cadila Healthcare Ltd. (India)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Cipla (India)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Hikma Pharmaceuticals (United Kingdom)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Aché (Brazil)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. AbbVie Inc. (United States)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
    • 7. Global Dexamethasone Drug Sale, by Application, Patient type, Distribution Channel, Formulation and Drug class (value, volume and price ) (2020-2025)
      • 7.1. Introduction
      • 7.2. Global Dexamethasone Drug (Value)
        • 7.2.1. Global Dexamethasone Drug by: Application (Value)
          • 7.2.1.1. Anti-inflammatory and immunosuppressant effects
          • 7.2.1.2. Respiratory Distress Syndrome
          • 7.2.1.3. COVID-19
          • 7.2.1.4. Others
        • 7.2.2. Global Dexamethasone Drug by: Patient type (Value)
          • 7.2.2.1. Adult
          • 7.2.2.2. Pediatric
          • 7.2.2.3. Geriatric
        • 7.2.3. Global Dexamethasone Drug by: Distribution Channel (Value)
          • 7.2.3.1. Online
          • 7.2.3.2. Offline
        • 7.2.4. Global Dexamethasone Drug by: Formulation (Value)
          • 7.2.4.1. Liquid
          • 7.2.4.2. Tablet
          • 7.2.4.3. Solution for injection
          • 7.2.4.4. Others
        • 7.2.5. Global Dexamethasone Drug by: Drug class (Value)
          • 7.2.5.1. Corticosteroid
          • 7.2.5.2. Glucocorticoid
      • 7.3. Global Dexamethasone Drug (Volume)
        • 7.3.1. Global Dexamethasone Drug by: Application (Volume)
          • 7.3.1.1. Anti-inflammatory and immunosuppressant effects
          • 7.3.1.2. Respiratory Distress Syndrome
          • 7.3.1.3. COVID-19
          • 7.3.1.4. Others
        • 7.3.2. Global Dexamethasone Drug by: Patient type (Volume)
          • 7.3.2.1. Adult
          • 7.3.2.2. Pediatric
          • 7.3.2.3. Geriatric
        • 7.3.3. Global Dexamethasone Drug by: Distribution Channel (Volume)
          • 7.3.3.1. Online
          • 7.3.3.2. Offline
        • 7.3.4. Global Dexamethasone Drug by: Formulation (Volume)
          • 7.3.4.1. Liquid
          • 7.3.4.2. Tablet
          • 7.3.4.3. Solution for injection
          • 7.3.4.4. Others
        • 7.3.5. Global Dexamethasone Drug by: Drug class (Volume)
          • 7.3.5.1. Corticosteroid
          • 7.3.5.2. Glucocorticoid
      • 7.4. Global Dexamethasone Drug (Price)
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Dexamethasone Drug: by Application(USD Million)
    • Table 2. Dexamethasone Drug: by Patient type(USD Million)
    • Table 3. Dexamethasone Drug: by Distribution Channel(USD Million)
    • Table 4. Dexamethasone Drug: by Formulation(USD Million)
    • Table 5. Dexamethasone Drug: by Drug class(USD Million)
    • Table 6. Dexamethasone Drug Sales: by Application(K Units)
    • Table 7. Dexamethasone Drug Sales: by Patient type(K Units)
    • Table 8. Dexamethasone Drug Sales: by Distribution Channel(K Units)
    • Table 9. Dexamethasone Drug Sales: by Formulation(K Units)
    • Table 10. Dexamethasone Drug Sales: by Drug class(K Units)
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Company Basic Information, Sales Area and Its Competitors
    • Table 17. Company Basic Information, Sales Area and Its Competitors
    • Table 18. Company Basic Information, Sales Area and Its Competitors
    • Table 19. Company Basic Information, Sales Area and Its Competitors
    • Table 20. Company Basic Information, Sales Area and Its Competitors
    • Table 21. Dexamethasone Drug: by Application(USD Million)
    • Table 22. Dexamethasone Drug: by Patient type(USD Million)
    • Table 23. Dexamethasone Drug: by Distribution Channel(USD Million)
    • Table 24. Dexamethasone Drug: by Formulation(USD Million)
    • Table 25. Dexamethasone Drug: by Drug class(USD Million)
    • Table 26. Dexamethasone Drug Sales: by Application(K Units)
    • Table 27. Dexamethasone Drug Sales: by Patient type(K Units)
    • Table 28. Dexamethasone Drug Sales: by Distribution Channel(K Units)
    • Table 29. Dexamethasone Drug Sales: by Formulation(K Units)
    • Table 30. Dexamethasone Drug Sales: by Drug class(K Units)
    • Table 31. Research Programs/Design for This Report
    • Table 32. Key Data Information from Secondary Sources
    • Table 33. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Dexamethasone Drug: by Application USD Million (2014-2019)
    • Figure 5. Global Dexamethasone Drug: by Patient type USD Million (2014-2019)
    • Figure 6. Global Dexamethasone Drug: by Distribution Channel USD Million (2014-2019)
    • Figure 7. Global Dexamethasone Drug: by Formulation USD Million (2014-2019)
    • Figure 8. Global Dexamethasone Drug: by Drug class USD Million (2014-2019)
    • Figure 9. Global Dexamethasone Drug: by Application K Units (2014-2019)
    • Figure 10. Global Dexamethasone Drug: by Patient type K Units (2014-2019)
    • Figure 11. Global Dexamethasone Drug: by Distribution Channel K Units (2014-2019)
    • Figure 12. Global Dexamethasone Drug: by Formulation K Units (2014-2019)
    • Figure 13. Global Dexamethasone Drug: by Drug class K Units (2014-2019)
    • Figure 14. Global Dexamethasone Drug share by Players 2019 (%)
    • Figure 15. Global Dexamethasone Drug share by Players (Top 3) 2019(%)
    • Figure 16. Global Dexamethasone Drug share by Players (Top 5) 2019(%)
    • Figure 17. BCG Matrix for key Companies
    • Figure 18. Sanofi (France) Revenue, Net Income and Gross profit
    • Figure 19. Sanofi (France) Revenue: by Geography 2019
    • Figure 20. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 21. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2019
    • Figure 22. Wockhardt Ltd. (India) Revenue, Net Income and Gross profit
    • Figure 23. Wockhardt Ltd. (India) Revenue: by Geography 2019
    • Figure 24. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
    • Figure 25. Eli Lilly and Company (United States) Revenue: by Geography 2019
    • Figure 26. Johnson & Johnson (J&J) (United States) Revenue, Net Income and Gross profit
    • Figure 27. Johnson & Johnson (J&J) (United States) Revenue: by Geography 2019
    • Figure 28. Cadila Healthcare Ltd. (India) Revenue, Net Income and Gross profit
    • Figure 29. Cadila Healthcare Ltd. (India) Revenue: by Geography 2019
    • Figure 30. Cipla (India) Revenue, Net Income and Gross profit
    • Figure 31. Cipla (India) Revenue: by Geography 2019
    • Figure 32. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 33. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2019
    • Figure 34. Aché (Brazil) Revenue, Net Income and Gross profit
    • Figure 35. Aché (Brazil) Revenue: by Geography 2019
    • Figure 36. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 37. AbbVie Inc. (United States) Revenue: by Geography 2019
    • Figure 38. Global Dexamethasone Drug: by Application USD Million (2020-2025)
    • Figure 39. Global Dexamethasone Drug: by Patient type USD Million (2020-2025)
    • Figure 40. Global Dexamethasone Drug: by Distribution Channel USD Million (2020-2025)
    • Figure 41. Global Dexamethasone Drug: by Formulation USD Million (2020-2025)
    • Figure 42. Global Dexamethasone Drug: by Drug class USD Million (2020-2025)
    • Figure 43. Global Dexamethasone Drug: by Application K Units (2020-2025)
    • Figure 44. Global Dexamethasone Drug: by Patient type K Units (2020-2025)
    • Figure 45. Global Dexamethasone Drug: by Distribution Channel K Units (2020-2025)
    • Figure 46. Global Dexamethasone Drug: by Formulation K Units (2020-2025)
    • Figure 47. Global Dexamethasone Drug: by Drug class K Units (2020-2025)
    Some of the key companies/manufacturers profiled in the report
    • Sanofi (France)
    • GlaxoSmithKline Plc (United Kingdom)
    • Wockhardt Ltd. (India)
    • Eli Lilly and Company (United States)
    • Johnson & Johnson (J&J) (United States)
    • Cadila Healthcare Ltd. (India)
    • Cipla (India)
    • Hikma Pharmaceuticals (United Kingdom)
    • Aché (Brazil)
    • AbbVie Inc. (United States)
    Additional players considered in the study are as follows:
    F Hoffmann-La Roche Ltd (Switzerland) , Novartis (Switzerland) , Pfizer Inc (United States)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation